NeoGenomics, Inc. revised earnings guidance for the fiscal year 2023. For the year, the company expects consolidated revenue to be in the range of $565 million to $575 million against previous guidance range of $555 million to $565 million. Net loss to be in the range of $107 million to $100 million against previous guidance range of $116 million to $108 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
13.99 USD | +1.16% | +0.72% | -13.54% |
05-28 | NeoGenomics, Inc. to Introduce Comprehensive Lung Solution & Feature Hematopathology Services At ASCO | CI |
05-02 | North American Morning Briefing : Stock Futures -3- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.54% | 1.77B | |
-25.19% | 7.67B | |
+70.32% | 4.38B | |
-7.18% | 2.52B | |
-44.46% | 2.23B | |
-21.62% | 1.52B | |
+17.46% | 1.21B | |
-43.89% | 1.14B | |
+19.93% | 997M | |
-7.28% | 955M |
- Stock Market
- Equities
- NEO Stock
- News NeoGenomics, Inc.
- NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023